Review of the latest systemic treatments for chronic non-infectious uveitis

References

• Gritz DC, Wong IG, Incidence and prevalence of uveitis in Northern California; the Northern California epidemiology of Uveitis study. Ophthalmology. 2004;111:491–500. discussion 500.
   PubMed Web of Science ®Google Scholar
• Tomkins-Netzer O, Talat L, Bar A, et al. Long-term clinical outcome and causes of vision loss in patients with uveitis. Ophthalmology. 2014;121:2387–2392.
   PubMed Web of Science ®Google Scholar
• Kruh JN, Yang P, Suelves AM, et al. Infliximab for the treatment of refractory noninfectious Uveitis: a study of 88 patients with long-term follow-up. Ophthalmology. 2014;121:358–364.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Michels H, Schumacher C, et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int. 2012;32:1121–1133.
   PubMed Web of Science ®Google Scholar
• Simonini G, Cimaz R, Jones GT, et al. Non-anti-TNF biologic modifier drugs in non-infectious refractory chronic uveitis: the current evidence from a systematic review. Semin Arthritis Rheum. 2015;45:238–250.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis nomenclature working G. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Kempen JH, Daniel E, Gangaputra S, et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the systemic immunosuppressive therapy for eye diseases (SITE) cohort study. Ophthalmic Epidemiol. 2008;15:47–55.
   PubMed Web of Science ®Google Scholar
• Ladas JG, Wheeler NC, Morhun PJ, et al. Laser flare-cell photometry: methodology and clinical applications. Surv Ophthalmol. 2005;50:27–47.
   PubMed Web of Science ®Google Scholar
• Balaskas K, Ballabeni P, Guex-Crosier Y, Retinal thickening in HLA-B27-associated acute anterior uveitis: evolution with time and association with severity of inflammatory activity. Invest Ophthalmol Vis Sci. 2012;53:6171–6177.
   PubMed Web of Science ®Google Scholar
• Foster CS, Kothari S, Anesi SD, et al. The ocular immunology and uveitis foundation preferred practice patterns of uveitis management. Surv Ophthalmol. 2016;61(1):1–17. doi:10.1016/j.survophthal.2015.07.001.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123:903–912.
   PubMed Web of Science ®Google Scholar
• Galor A, Perez VL, Hammel JP, et al. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113:2317–2323.
   PubMed Web of Science ®Google Scholar
• Mamo JG. The rate of visual loss in Behçet’s disease. Arch Ophthalmol. 1970;84:451–452.
   PubMedGoogle Scholar
• Wakefield D. Methylprednisolone pulse therapy in severe anterior uveitis. Aust N Z J Ophthalmol. 1985;13:411–415.
   PubMedGoogle Scholar
• Markomichelakis N, Delicha E, Masselos S, et al. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet’s disease: a comparative 4-week study. Rheumatology (Oxford). 2011;50:593–597.
   PubMed Web of Science ®Google Scholar
• Baeten D, Van Hagen PM. Use of TNF blockers and other targeted therapies in rare refractory immune-mediated inflammatory diseases: evidence-based or rational? Ann Rheum Dis. 2010;69:2067–2073.
   PubMed Web of Science ®Google Scholar
• Vidovic-Valentincic N, Kraut A, Hawlina M, et al. Intermediate uveitis: long-term course and visual outcome. Br J Ophthalmol. 2009;93:477–480.
   PubMed Web of Science ®Google Scholar
• Jalil A, Yin K, Coyle L, et al. Vision-related quality of life and employment status in patients with uveitis of working age: a prospective study. Ocul Immunol Inflamm. 2012;20:262–265.
   PubMed Web of Science ®Google Scholar
• Van Gelder RN, Lee BS, Uveitis treatments: at what cost quality? Ophthalmology. 2014;121:1852–1854.
   PubMed Web of Science ®Google Scholar
• Ozzello DJ, Palestine AG. Factors affecting therapeutic decisions in intermediate and posterior uveitis. Am J Ophthalmol. 2015;159:213–220.
   PubMed Web of Science ®Google Scholar
• Caspi RR, A look at autoimmunity and inflammation in the eye. J Clin Invest. 2010;120:3073–3083.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119:651–665.
   PubMed Web of Science ®Google Scholar
• Valentincic NV, De Groot-Mijnes JD, Kraut A, et al. Intraocular and serum cytokine profiles in patients with intermediate uveitis. Mol Vis. 2011;17:2003–2010.
   PubMed Web of Science ®Google Scholar
• Hayashi S, Guex-Crosier Y, Delvaux A, et al. Interleukin 10 inhibits inflammatory cells infiltration in endotoxin-induced uveitis. Graefes Arch Clin Exp Ophthalmol. 1996;234:633–636.
   PubMed Web of Science ®Google Scholar
• Guex-Crosier Y, Raber J, Chan CC, et al. Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol. 1997;158:452–458.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A. 1999;96:7462–7466.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Thompson DJ, Li Z, et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun. 2003;21:283–293.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Hatef E, Kayen B, et al. A cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the United States. Ophthalmology. 2011;118:184–190.
   PubMed Web of Science ®Google Scholar
• Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids–new mechanisms for old drugs. N Engl J Med. 2005;353:1711–1723.
   PubMed Web of Science ®Google Scholar
• Takakura A, Tessler HH, Goldstein DA, et al. Viral retinitis following intraocular or periocular corticosteroid administration: a case series and comprehensive review of the literature. Ocul Immunol Inflamm. 2014;22:175–182.
   PubMed Web of Science ®Google Scholar
• Kothari S, Foster CS, Pistilli M, et al. The risk of intraocular pressure elevation in pediatric noninfectious uveitis. Ophthalmology. 2015;122:1987–2001.
   PubMed Web of Science ®Google Scholar
• Barry RJ, Nguyen QD, Lee RW, et al. Pharmacotherapy for uveitis: current management and emerging therapy. Clin Ophthalmol. 2014;8:1891–1911.
   PubMedGoogle Scholar
• Charkoudian LD, Ying G-S, Pujari SS, et al. High-dose intravenous corticosteroids for ocular inflammatory diseases. Ocul Immunol Inflamm. 2012;20:91–99.
   PubMed Web of Science ®Google Scholar
• Yi X, Yang P, Sun M, et al. Decreased 1,25-Dihydroxyvitamin D3 level is involved in the pathogenesis of Vogt–Koyanagi–Harada (VKH) disease. Mol Vis. 2011;17:673–679.
   PubMed Web of Science ®Google Scholar
• Loh AR, Acharya NR. Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uveitis. Am J Ophthalmol. 2010;150:534–542 e532.
   PubMed Web of Science ®Google Scholar
• Schewitz-Bowers LP, Lait PJ, Copland DA, et al. Glucocorticoid-resistant Th17 cells are selectively attenuated by cyclosporine A. Proc Natl Acad Sci U S A. 2015;112:4080–4085.
   PubMed Web of Science ®Google Scholar
• Kacmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117:576–584.
   PubMed Web of Science ®Google Scholar
• Mathews D, Mathews J, Jones NP. Low-dose cyclosporine treatment for sight-threatening uveitis: efficacy, toxicity, and tolerance. Indian J Ophthalmol. 2010;58:55–58.
   PubMed Web of Science ®Google Scholar
• Lee SH, Chung H, Yu HG. Clinical outcomes of cyclosporine treatment for noninfectious uveitis. Korean J Ophthalmol. 2012;26:21–25.
   PubMedGoogle Scholar
• Orsoni JG, Zavota L, Mora P, et al. Discontinuous drug combination therapy in autoimmune ocular disorders. Acta Ophthalmol. 2009;87:340–345.
   PubMed Web of Science ®Google Scholar
• Gion N, Stavrou P, Foster CS. Immunomodulatory therapy for chronic tubulointerstitial nephritis-associated uveitis. Am J Ophthalmol. 2000;129:764–768.
   PubMed Web of Science ®Google Scholar
• Le Hoang P, Girard B, Deray G, et al. Cyclosporine in the treatment of birdshot retinochoroidopathy. Transplant Proc. 1988;20:128–130.
   PubMed Web of Science ®Google Scholar
• Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy. Ophthalmology. 1994;101:822–831.
   PubMed Web of Science ®Google Scholar
• Cuchacovich M, Solanes F, Diaz G, et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic Vogt–Koyanagi–Harada disease. Ocul Immunol Inflamm. 2010;18:200–207.
   PubMed Web of Science ®Google Scholar
• Damico FM, Kiss S, Young LH. Vogt–Koyanagi–Harada disease. Semin Ophthalmol. 2005;20:183–190.
   PubMedGoogle Scholar
• Arevalo JF, Lasave AF, Al Jindan MY, et al. Uveitis in Behçet disease in a tertiary center over 25 years: the KKESH uveitis survey study group. Am J Ophthalmol. 2015;159:177-184 e171-172.
   Web of Science ®Google Scholar
• Markomichelakis NN, Theodossiadis PG, Pantelia E, et al. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138:648–650.
   PubMed Web of Science ®Google Scholar
• Lapadula G. [Biologic therapy with anti-TNFα in spondyloarthritides and other autoimmune diseases]. Reumatismo. 2005;57:22–29.
   PubMedGoogle Scholar
• Lindstedt EW, Baarsma GS, Kuijpers RW, et al. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol. 2005;89:533–536.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Sugita S, Tanaka H, et al. Timing of recurrent uveitis in patients with Behcet’s disease receiving infliximab treatment. Br J Ophthalmol. 2011;95:205–208.
   PubMed Web of Science ®Google Scholar
• Deuter C, Stubiger N, Zierhut M. Interferon-α therapy in noninfectious uveitis. Dev Ophthalmol. 2012;51:90–97.
   PubMedGoogle Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785–796 e783.
   PubMed Web of Science ®Google Scholar
• Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. 2005;123:634–641.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Hokama H, Katagiri Y, et al. Effects of intravitreal injection of tacrolimus (FK506) in experimental uveitis. Curr Eye Res. 2005;30:93–101.
   PubMed Web of Science ®Google Scholar
• Kawashima H, Fujino Y, Mochizuki M. Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats. Invest Ophthalmol Vis Sci. 1988;29:1265–1271.
   PubMed Web of Science ®Google Scholar
• Oh-i K, Keino H, Goto H, et al. Intravitreal injection of Tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in Rats. Br J Ophthalmol. 2007;91:237–242.
   PubMed Web of Science ®Google Scholar
• Zhang R, He R, Qian J, et al. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. Invest Ophthalmol Vis Sci. 2010;51:3575–3582.
   PubMed Web of Science ®Google Scholar
• Hogan AC, McAvoy CE, Dick AD, et al. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology. 2007;114:1000–1006.
   PubMed Web of Science ®Google Scholar
• Figueroa MS, Ciancas E, Orte L. Long-term follow-up of tacrolimus treatment in immune posterior uveitis. Eur J Ophthalmol. 2007;17:69–74.
   PubMed Web of Science ®Google Scholar
• Lee RW, Greenwood R, Taylor H, et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology. 2012;119:1223–1230.
   PubMed Web of Science ®Google Scholar
• Roberge FG, Xu D, Chan CC, et al. Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction. Curr Eye Res. 1993;12:197–203.
   PubMed Web of Science ®Google Scholar
• Martin DF, DeBarge LR, Nussenblatt RB, et al. Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol. 1995;154:922–927.
   PubMed Web of Science ®Google Scholar
• Shanmuganathan VA, Casely EM, Raj D, et al. The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol. 2005;89:666–669.
   PubMed Web of Science ®Google Scholar
• Phillips BN, Wroblewski KJ. A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis. J Ophthalmic Inflamm Infect. 2011;1:29–34.
   Google Scholar
• Mallory A, Kern F Jr. Drug-induced pancreatitis: a critical review. Gastroenterology. 1980;78:813–820.
   PubMed Web of Science ®Google Scholar
• Konstantopoulou M, Belgi A, Griffiths KD, et al. Azathioprine-induced pancytopenia in a patient with pompholyx and deficiency of erythrocyte thiopurine methyltransferase. Bmj. 2005;330:350–351.
   PubMed Web of Science ®Google Scholar
• Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148:500–509.
   PubMed Web of Science ®Google Scholar
• Goebel JC, Roesel M, Heinz C, et al. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Br J Ophthalmol. 2011;95:209–213.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Sadeghi Abdollahi B, Shams H, et al. Combination of pulse cyclophosphamide and azathioprine in ocular manifestations of Behcet’s disease: longitudinal study of up to 10 years. Int J Rheum Dis. 2014;17:444–452.
   PubMed Web of Science ®Google Scholar
• Becker MD, Smith JR, Max R, et al. Management of sight-threatening uveitis: new therapeutic options. Drugs. 2005;65:497–519.
   PubMed Web of Science ®Google Scholar
• Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116:2188–2198.
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Schenck S, Niewerth M, et al. Impact of anti-inflammatory treatment on the onset of uveitis in juvenile idiopathic arthritis: longitudinal analysis from a nation-wide paediatric rheumatology database. Arthritis Care Res (Hoboken). 2016;68(1):46–54. doi:10.1002/acr.22649
   PubMed Web of Science ®Google Scholar
• Rathinam SR, Babu M, Thundikandy R, et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology. 2014;121:1863–1870.
   PubMed Web of Science ®Google Scholar
• Simonini G, Paudyal P, Jones GT, et al. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology (Oxford). 2013;52:825–831.
   PubMed Web of Science ®Google Scholar
• Sahin O, Ziaei A. The role of methotrexate in resolving ocular inflammation after specific therapy for presumed latent syphilitic uveitis and presumed tuberculosis-related uveitis. Retina. 2014;34:1451–1459.
   PubMed Web of Science ®Google Scholar
• Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008;115:1826–1832.
   PubMed Web of Science ®Google Scholar
• Mackensen F, Jakob E, Springer C, et al. Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol. 2013;156:478–486.
   PubMed Web of Science ®Google Scholar
• Fulton B, Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs. 1996;51:278–298.
   PubMed Web of Science ®Google Scholar
• Teoh SC, Hogan AC, Dick AD, et al. Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol. 2008;146:752–760. 760 e751-753.
   PubMed Web of Science ®Google Scholar
• Siepmann K, Huber M, Stubiger N, et al. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis: a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol. 2006;244:788–794.
   PubMed Web of Science ®Google Scholar
• Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008;115:1416–1421. 1421 e1411.
   PubMed Web of Science ®Google Scholar
• Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149:423–432.
   PubMed Web of Science ®Google Scholar
• Bhat P, Cervantes-Castaneda RA, Doctor PP, et al. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis. Ocul Immunol Inflamm. 2009;17:185–190.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Hemachandran S, Al-Mezaine HS, et al. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt–Koyanagi–Harada disease. Acta Ophthalmol. 2012;90:e603–608.
   PubMed Web of Science ®Google Scholar
• Yalcindag FN, Amer R, Forrester JV. Mycophenolate mofetil in the treatment of ocular inflammation in ANCA-associated vasculitis. J Ocul Pharmacol Ther. 2008;24:249–254.
   PubMed Web of Science ®Google Scholar
• Klisovic DD. Mycophenolate mofetil use in the treatment of noninfectious uveitis. Dev Ophthalmol. 2012;51:57–62.
   PubMedGoogle Scholar
• Doycheva D, Zierhut M, Blumenstock G, et al. Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2011;249:1235–1243.
   PubMed Web of Science ®Google Scholar
• Neri P, Mariotti C, Cimino L, et al. Long-term control of cystoid macular oedema in noninfectious uveitis with Mycophenolate Mofetil. Int Ophthalmol. 2009;29:127–133.
   PubMedGoogle Scholar
• Doycheva D, Zierhut M, Blumenstock G, et al. Mycophenolate mofetil in the therapy of uveitic macular edema–long-term results. Ocul Immunol Inflamm. 2012;20:203–211.
   PubMed Web of Science ®Google Scholar
• Chang PY, Giuliari GP, Shaikh M, et al. Mycophenolate mofetil monotherapy in the management of paediatric uveitis. Eye (Lond). 2011;25:427–435.
   PubMed Web of Science ®Google Scholar
• Doycheva D, Deuter C, Stuebiger N, et al. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol. 2007;91:180–184.
   PubMed Web of Science ®Google Scholar
• Roy M. Early clinical experience with leflunomide in uveitis. Can J Ophthalmol. 2007;42:634.
   PubMed Web of Science ®Google Scholar
• Fang C-B, Zhou D-X, Zhan S-X, et al. Amelioration of experimental autoimmune uveitis by leflunomide in Lewis rats. PLoS One. 2013;8:e62071.
   PubMed Web of Science ®Google Scholar
• Molina C, Modesto C, Martin-Begue N, et al. Leflunomide, a valid and safe drug for the treatment of chronic anterior uveitis associated with juvenile idiopathic arthritis. Clin Rheumatol. 2013;32:1673–1675.
   PubMed Web of Science ®Google Scholar
• Bichler J, Benseler SM, Krumrey-Langkammerer M, et al. Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis. Scand J Rheumatol. 2015;44(4):280–283. doi:10.3109/03009742.2015.1013983.
   PubMed Web of Science ®Google Scholar
• Kotter I, Gunaydin I, Treusch M, et al. The use of interferon-alpha in Behçet’s disease--review of the literature and possible mechanisms of action. Adv Exp Med Biol. 2003;528:503–509.
   PubMed Web of Science ®Google Scholar
• Treusch M, Vonthein R, Baur M, et al. Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet’s disease. Rheumatology (Oxford). 2004;43:1275–1282.
   PubMed Web of Science ®Google Scholar
• Park J-Y, Chung Y-R, Lee K, et al. Clinical experience of interferon alfa-2a treatment for refractory uveitis in Behçet’s disease. Yonsei Med J. 2015;56:1158–1162.
   PubMed Web of Science ®Google Scholar
• Karagiannidis I, Zouboulis CC. [Systemic Adamantiades-Behçet’s disease: adverse effects of an otherwise successful therapy with interferon-α-2a]. Dtsch Med Wochenschr. 2015;140:112–113.
   PubMed Web of Science ®Google Scholar
• Touitou V, Sene D, Fardeau C, et al. Interferon-alpha2a and Vogt–Koyanagi–Harada disease: a double-edged sword? Int Ophthalmol. 2007;27:211–215.
   PubMedGoogle Scholar
• Deuter CM, Koetter I, Guenaydin I, et al. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina. 2006;26:786–791.
   PubMed Web of Science ®Google Scholar
• Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol. 2008;146:837-44.e1.
   PubMed Web of Science ®Google Scholar
• Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91:335–339.
   PubMed Web of Science ®Google Scholar
• Guillaume-Czitrom S, Berger C, Pajot C, et al. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet’s disease. Rheumatology (Oxford). 2007;46:1570–1573.
   PubMed Web of Science ®Google Scholar
• Krause L, Altenburg A, Pleyer U, et al. Longterm visual prognosis of patients with ocular Adamantiades-Behçet’s disease treated with interferon-alpha-2a. J Rheumatol. 2008;35:896–903.
   PubMed Web of Science ®Google Scholar
• Sobaci G, Erdem U, Durukan AH, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet’s uveitis refractory to conventional treatments. Ophthalmology. 2010;117:1430–1435.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Zierhut M, Mohle A, et al. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet’s disease. Arthritis Rheum. 2010;62:2796–2805.
   PubMed Web of Science ®Google Scholar
• Yalcindag FN, Uzun A. Results of interferon alpha-2a therapy in patients with Behcet’s disease. J Ocul Pharmacol Ther. 2012;28:439–443.
   PubMed Web of Science ®Google Scholar
• Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol. 2011;129:288–294.
   PubMed Web of Science ®Google Scholar
• Onal S, Kazokoglu H, Koc A, et al. Low dose and dose escalating therapy of interferon alfa-2a in the treatment of refractory and sight-threatening Behçet’s uveitis. Clin Exp Rheumatol. 2009;27:S113–114.
   PubMed Web of Science ®Google Scholar
• Onal S, Kazokoglu H, Direskeneli H, et al. Low-dose interferon alfa-2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol. 2009;147:1109–1110. author reply 1110.
   PubMed Web of Science ®Google Scholar
• Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423–431.
   PubMed Web of Science ®Google Scholar
• Evereklioglu C. Ocular Behçet disease: current therapeutic approaches. Curr Opin Ophthalmol. 2011;22:508–516.
   PubMed Web of Science ®Google Scholar
• Kotter I, Zierhut M, Eckstein A, et al. Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet’s disease with sight-threatening retinal vasculitis. Adv Exp Med Biol. 2003;528:521–523.
   PubMed Web of Science ®Google Scholar
• Touitou V, Bodaghi B, Cassoux N, et al. Vogt–Koyanagi–Harada disease in patients with chronic hepatitis C. Am J Ophthalmol. 2005;140:949–952.
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Tzaribachev N, Deuter C, et al. Interferon-alpha--a new therapeutic option in refractory juvenile Behçet’s disease with CNS involvement. Rheumatology (Oxford). 2008;47:1051–1053.
   PubMed Web of Science ®Google Scholar
• Matucci A, Maggi E, Vultaggio A. Cellular and humoral immune responses during tuberculosis infection: useful knowledge in the era of biological agents. J Rheumatol Suppl. 2014;91:17–23.
   PubMedGoogle Scholar
• Vigano M, Degasperi E, Aghemo A, et al. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther. 2012;12:193–207.
   PubMed Web of Science ®Google Scholar
• Camussi G, Lupia E. The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs. 1998;55:613–620.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Brennan FM, Williams RO, et al. Evaluation of the role of cytokines in autoimmune disease: the importance of TNF alpha in rheumatoid arthritis. Prog Growth Factor Res. 1992;4:247–255.
   PubMedGoogle Scholar
• Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007;18:481–486.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Roberto Perez A, Diaz-Lagares C, et al. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 2010;9:188–193.
   PubMed Web of Science ®Google Scholar
• Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:889–894.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Chen L, Fraunfelder FW, et al. Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol. 2013;155:183–189 e181.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. Jama. 2013;309:887–895.
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Yilmaz T, Onal S, Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis. Ocul Immunol Inflamm. 2013;21:19–27.
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Salazar-Mendez R, Yilmaz T, Treatment of severe non-infectious uveitis in high-risk conditions (Part I): pregnancy and malignancies, management and safety issues. Expert Opin Drug Saf. 2015;14:1071–1086.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Lowder CY, Goldstein DA, et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol. 2013;97:481–486.
   PubMed Web of Science ®Google Scholar
• Dobner BC, Max R, Becker MD, et al. A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol. 2013;97:134–138.
   PubMed Web of Science ®Google Scholar
• Garcia-De-Vicuna C, Diaz-Llopis M, Salom D, et al. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediators Inflamm. 2013;2013:560632.
   PubMed Web of Science ®Google Scholar
• Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken). 2011;63:612–618.
   PubMed Web of Science ®Google Scholar
• Simonini G, Taddio A, Cattalini M, et al. Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis. Pediatr Rheumatol Online J. 2013;11:16.
   PubMed Web of Science ®Google Scholar
• Klotsche J, Niewerth M, Haas JP, et al. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Ann Rheum Dis. 2015 Apr 29. pii: annrheumdis-2014-206747. doi:10.1136/annrheumdis-annrheumdis-2014-206747. [Epub ahead of print].
   Google Scholar
• Diaz-Llopis M, Salom D, Garcia-de-Vicuna C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119:1575–1581.
   PubMed Web of Science ®Google Scholar
• Calleja S, Cordero-Coma M, Rodriguez E, et al. Adalimumab specifically induces CD3(+) CD4(+) CD25(high) Foxp3(+) CD127(-) T-regulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno-mediated uveitis: a non-randomized pilot intervention study. Eye (Lond). 2012;26:468–477.
   PubMed Web of Science ®Google Scholar
• Van Denderen JC, Visman IM, Nurmohamed MT, et al. Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis. J Rheumatol. 2014;41:1843–1848.
   PubMed Web of Science ®Google Scholar
• Interlandi E, Leccese P, Olivieri I, et al. Adalimumab for treatment of severe Behçet’s uveitis: a retrospective long-term follow-up study. Clin Exp Rheumatol. 2014;32:S58–62.
   PubMed Web of Science ®Google Scholar
• Hernandez Garfella ML, Palomares Fort P, Roman Ivorra JA, et al. Aqueous humor levels of different interleukins 1-β, 2, 6 and 10, tumor necrosis factor-α and vascular endothelial growth factor in uveitis treated with adalimumab. J Ophthalmic Vis Res. 2015;10:49–54.
   PubMedGoogle Scholar
• Cordero-Coma M, Calleja S, Llorente M, et al. Serum cytokine profile in adalimumab-treated refractory uveitis patients: decreased IL-22 correlates with clinical responses. Ocul Immunol Inflamm. 2013;21:212–219.
   PubMed Web of Science ®Google Scholar
• Hamam RN, Barikian AW, Antonios RS, et al. Intravitreal adalimumab in active noninfectious uveitis: a pilot study. Ocul Immunol Inflamm. 2015 Aug 24:1–8. [Epub ahead of print].
   PubMedGoogle Scholar
• Jeroudi A, Angeles-Han ST, Yeh S. Efficacy of adalimumab for pediatric Vogt–Koyanagi–Harada syndrome. Ophthalmic Surg Lasers Imaging Retina. 2014;45:332–334.
   PubMed Web of Science ®Google Scholar
• Erckens RJ, Mostard RL, Wijnen PA, et al. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250:713–720.
   PubMed Web of Science ®Google Scholar
• Riancho-Zarrabeitia L, Calvo-Rio V, Blanco R, et al. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients. Semin Arthritis Rheum. 2015;45:361–368.
   PubMed Web of Science ®Google Scholar
• Chinchurreta Capote A, Requena Jimenez JM, Lorenzo Soto M, et al. Effectiveness of adalimumab for refractory serpiginous choroiditis. Ocul Immunol Inflamm. 2014;22:405–408.
   PubMed Web of Science ®Google Scholar
• Ermertcan AT, Emre S, Ozturk F, et al. Psoriatic uveitis responding to adalimumab therapy. Int J Dermatol. 2014;53:e271–273.
   PubMed Web of Science ®Google Scholar
• Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med. 2013;173:1416–1428.
   PubMed Web of Science ®Google Scholar
• Simonini G, Katie D, Cimaz R, et al. Does switching anti-TNFα biologic agents represent an effective option in childhood chronic uveitis: the evidence from a systematic review and meta-analysis approach. Semin Arthritis Rheum. 2014;44:39–46.
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Sobrin L. Anti–tumor necrosis factor-α therapy in uveitis. Surv Ophthalmol. 2015;60:575–589.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet’s disease: a multicenter study. Ophthalmology. 2014;121:1877–1884.
   PubMed Web of Science ®Google Scholar
• Keino H, Okada AA, Watanabe T, et al. Long-term efficacy of infliximab on background vascular leakage in patients with Behçet’s disease. Eye (Lond). 2014;28:1100–1106.
   PubMed Web of Science ®Google Scholar
• Kaburaki T, Namba K, Sonoda K-H, et al. Behçet’s disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol. 2014;58:120–130.
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Kawazoe Y, Kamoi K, et al. Clinical course of patients with Behçet’s uveitis following discontinuation of infliximab therapy. Jpn J Ophthalmol. 2014;58:75–80.
   PubMed Web of Science ®Google Scholar
• Sakai T, Watanabe H, Kuroyanagi K, et al. Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis. Br J Ophthalmol. 2013;97:338–342.
   PubMed Web of Science ®Google Scholar
• Al Rashidi S, Al Fawaz A, Kangave D, et al. Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab. Ocul Immunol Inflamm. 2013;21:468–474.
   PubMed Web of Science ®Google Scholar
• Okada AA, Goto H, Ohno S, et al. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol. 2012;130:592–598. Ocular Behcet’s Disease Research Group Of J.
   PubMed Web of Science ®Google Scholar
• Kurata I, Tsuboi H, Takahashi H, et al. Successful Treatment with Infliximab for Refractory Uveitis in a Hemodialysis Patient with Behçet’s Disease and a Review of the Literature for Infliximab Use in Patients on Hemodialysis. Intern Med. 2015;54:1553–1557.
   PubMed Web of Science ®Google Scholar
• Kam KW, Tam LS, Tam MK, et al. Infliximab in the treatment of refractory ocular inflammatory diseases. Asia Pac J Ophthalmol (Phila). 2015;4:19–24.
   PubMed Web of Science ®Google Scholar
• Sharma PK, Markov GT, Bajwa A, et al. Long-term efficacy of systemic infliximab in recalcitrant retinal vasculitis. Retina. 2015;35:2641–2646.
   PubMed Web of Science ®Google Scholar
• Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362–1368.
   PubMed Web of Science ®Google Scholar
• Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014;22:96–101.
   PubMed Web of Science ®Google Scholar
• Artornsombudh P, Gevorgyan O, Payal A, et al. Infliximab treatment of patients with birdshot retinochoroidopathy. Ophthalmology. 2013;120:588–592.
   PubMed Web of Science ®Google Scholar
• Zmuda M, Tiev KP, Knoeri J, et al. Successful use of infliximab therapy in sight-threatening corticosteroid-resistant Vogt–Koyanagi–Harada disease. Ocul Immunol Inflamm. 2013;21:310–316.
   PubMed Web of Science ®Google Scholar
• Sukumaran S, Marzan K, Shaham B, et al. High dose infliximab in the treatment of refractory uveitis: does dose matter? ISRN Rheumatol. 2012;2012:765380.
   PubMedGoogle Scholar
• Farvardin M, Afarid M, Mehryar M, et al. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina. 2010;30:1530–1535.
   PubMed Web of Science ®Google Scholar
• Markomichelakis N, Delicha E, Masselos S, et al. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients. Am J Ophthalmol. 2012;154:534–541.
   PubMed Web of Science ®Google Scholar
• Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093–1101.
   PubMed Web of Science ®Google Scholar
• Farah RE, Shay MD. Pulmonary sarcoidosis associated with etanercept therapy. Pharmacotherapy. 2007;27:1446–1448.
   PubMed Web of Science ®Google Scholar
• Saeed MU, Raza SH, Goyal S, et al. Etanercept in methotrexate-resistant JIA-related uveitis. Semin Ophthalmol. 2014;29:1–3.
   PubMed Web of Science ®Google Scholar
• Marotte H, Cimaz R. Etanercept - TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers? Expert Opin Biol Ther. 2014;14:569–572.
   PubMed Web of Science ®Google Scholar
• Tynjala P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66:548–550.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52:2447–2451.
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Becker I, Horneff G. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry. Arthritis Care Res (Hoboken). 2015;67:1529–1535.
   PubMed Web of Science ®Google Scholar
• Brito-Zeron P, Perez-Alvarez R, Ramos-Casals M. Etanercept and uveitis: friends or foes? Curr Med Res Opin. 2015;31:251–252.
   PubMed Web of Science ®Google Scholar
• Raffeiner B, Ometto F, Bernardi L, et al. Inefficacy or paradoxical effect? Uveitis in ankylosing spondylitis treated with etanercept. Case Rep Med. 2014;2014:471319.
   PubMedGoogle Scholar
• Sieper J, Koenig A, Baumgartner S, et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis. 2010;69:226–229.
   PubMed Web of Science ®Google Scholar
• Wang F, Wang N-S. Etanercept therapy-associated acute uveitis: a case report and literature review. Clin Exp Rheumatol. 2009;27:838–839.
   PubMed Web of Science ®Google Scholar
• Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res. 2010;35:751–756.
   PubMed Web of Science ®Google Scholar
• Gaujoux-Viala C, Giampietro C, Gaujoux T, et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol. 2012;39:233–239.
   PubMed Web of Science ®Google Scholar
• Killian M, Touraine R, Amouzougan A, et al. Impact of genetic predisposition of de novo uveitis with etanercept in ankylosing spondylitis. Ann Rheum Dis. 2015;74:e22.
   PubMed Web of Science ®Google Scholar
• Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. 2006;65:1631–1634.
   PubMed Web of Science ®Google Scholar
• Cobo-Ibanez T, Del Carmen Ordonez M, Munoz-Fernandez S, et al. Do TNF-blockers reduce or induce uveitis? Rheumatology (Oxford). 2008;47:731–732.
   PubMed Web of Science ®Google Scholar
• Manzano RP, Carvounis PE, Albini TA, et al. Etanercept monotherapy induces complete resolution of cystoid macular edema in a patient with intermediate uveitis. Retin Cases Brief Rep. 2007;1:261–263.
   PubMedGoogle Scholar
• Fukuda K, Kumagai N, Nakamura H, et al. [Successful treatment of cystoid macular edema with etanercept in a patient with rheumatoid arthritis associated panuveitis]. Nippon Ganka Gakkai Zasshi. 2008;112:51–57.
   PubMedGoogle Scholar
• Mohammed RH. Etanercept therapy in Behçet’s disease. The tight control strategy in refractory disease. Z Rheumatol. 2014;73:650–656.
   PubMed Web of Science ®Google Scholar
• Hashkes PJ, Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol. 2003;21:645–646.
   PubMed Web of Science ®Google Scholar
• Suzuki J, Goto H. Uveitis associated with sarcoidosis exacerbated by etanercept therapy. Jpn J Ophthalmol. 2009;53:439–440.
   PubMed Web of Science ®Google Scholar
• Durel CA, Feurer E, Pialat JB, et al. Confavreux CB. Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis. BMC Neurol. 2013;13:212.
   PubMed Web of Science ®Google Scholar
• Berrios I, Jun-O’Connell A, Ghiran S, et al. A case of neurosarcoidosis secondary to treatment of etanercept and review of the literature. BMJ Case Rep. 2015 Jul 6;pii: bcr2014208188. doi:10.1136/bcr-2014-208188.
   PubMedGoogle Scholar
• Cordero-Coma M, Salom D, Diaz-Llopis M, et al. Golimumab for uveitis. Ophthalmology. 2011;118:1892 e1893–1894.
   Google Scholar
• William M, Faez S, Papaliodis GN, et al. Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect. 2012;2:231–233.
   PubMedGoogle Scholar
• Miserocchi E, Modorati G, Pontikaki I, et al. Golimumab treatment for complicated uveitis. Clin Exp Rheumatol. 2013;31:320–321.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Pontikaki I, et al. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm. 2014;22:90–95.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Victoria HM, Llorenc V, et al. Behçet disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm. 2013;21:160–162.
   PubMed Web of Science ®Google Scholar
• Faez S, Lobo A-M, Sobrin L, et al. Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series. Clin Experiment Ophthalmol. 2014;42:392–395.
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Calvo-Rio V, Adan A, et al. Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediators Inflamm. 2014;2014:717598.
   PubMed Web of Science ®Google Scholar
• Calvo-Rio V, De La Hera D, Blanco R, et al. Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review. Clin Exp Rheumatol. 2014;32:864–868.
   PubMed Web of Science ®Google Scholar
• Llorenç V, Mesquida M, Sainz De La Maza M, et al. Certolizumab Pegol, a new anti-TNF-alpha in the Armamentarium against Ocular Inflammation. Ocul Immunol Inflamm. 2015 Aug 24:1–6. [Epub ahead of print].
   Google Scholar
• Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286–292. quiz e224.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Simon A, Van Der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11:633–652.
   PubMed Web of Science ®Google Scholar
• Teoh SC, Sharma S, Hogan A, et al. Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol. 2007;91:263–264.
   PubMed Web of Science ®Google Scholar
• Arostegui JI, Arnal C, Merino R, et al. NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum. 2007;56:3805–3813.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol. 2015;34:1293–1301.
   PubMed Web of Science ®Google Scholar
• Blech M, Peter D, Fischer P, et al. One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β. J Mol Biol. 2013;425:94–111.
   PubMed Web of Science ®Google Scholar
• Gul A, Tugal-Tutkun I, Dinarello CA, et al. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis. 2012;71:563–566.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Cantarini L, Vitale A, et al. Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediators Inflamm. 2015;2015:194864.
   PubMed Web of Science ®Google Scholar
• Simonini G, Xu Z, Caputo R, et al. Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. Arthritis Rheum. 2013;65:513–518.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Borri M, et al. Successful use of canakinumab in a patient with resistant Behçet’s disease. Clin Exp Rheumatol. 2012;30(3 Suppl 72):S115.
   Google Scholar
• Ugurlu S, Ucar D, Seyahi E, et al. Canakinumab in a patient with juvenile Behcet’s syndrome with refractory eye disease. Ann Rheum Dis. 2012;71:1589–1591.
   PubMed Web of Science ®Google Scholar
• Yeh S, Wroblewski K, Buggage R, et al. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun. 2008;31:91–97.
   PubMed Web of Science ®Google Scholar
• Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40:1830–1835.
   PubMed Web of Science ®Google Scholar
• Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265:621–636.
   PubMed Web of Science ®Google Scholar
• Kishimoto T. The biology of interleukin-6. Blood. 1989;74:1–10.
   PubMed Web of Science ®Google Scholar
• Nakahara H, Song J, Sugimoto M, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 2003;48:1521–1529.
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Sonoda K-H, Ohguro N, et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford). 2009;48:347–354.
   PubMed Web of Science ®Google Scholar
• Tanaka T. Can IL-6 blockade rectify imbalance between Tregs and Th17 cells? Immunotherapy. 2013;5:695–697.
   PubMed Web of Science ®Google Scholar
• Yao X, Huang J, Zhong H, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141:125–139.
   PubMed Web of Science ®Google Scholar
• Richez C, Barnetche T, Khoryati L, et al. Tocilizumab treatment decreases circulating myeloid dendritic cells and monocytes, 2 components of the myeloid lineage. J Rheumatol. 2012;39:1192–1197.
   PubMed Web of Science ®Google Scholar
• Sato T, Minakuchi S, Mochizuki M, et al. Acute anterior uveitis after discontinuation of tocilizumab in a patient with rheumatoid arthritis. Clin Ophthalmol. 2014;8:187–190.
   PubMedGoogle Scholar
• Muselier A, Bielefeld P, Bidot S, et al. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm. 2011;19:382–383.
   PubMed Web of Science ®Google Scholar
• Adan A, Mesquida M, Llorenc V, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251:2627–2632.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorenc V, et al. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology. 2014;121:2380–2386.
   PubMed Web of Science ®Google Scholar
• Arida A, Sfikakis PP. Anti-cytokine biologic treatment beyond anti-TNF in Behçet’s disease. Clin Exp Rheumatol. 2014;32:S149–155.
   PubMed Web of Science ®Google Scholar
• Tsang AC, Roth J, Gottlieb C. Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient. Ocul Immunol Inflamm. 2014;22:155–157.
   PubMed Web of Science ®Google Scholar
• Calvo-Rio V, De La Hera D, Beltran-Catalan E, et al. Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. Clin Exp Rheumatol. 2014;32:S54–57.
   PubMed Web of Science ®Google Scholar
• Papo M, Bielefeld P, Vallet H, et al. Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol. 2014;32:S75–79.
   PubMed Web of Science ®Google Scholar
• Oshitari T, Kajita F, Tobe A, et al. Refractory uveitis in patient with Castleman disease successfully treated with tocilizumab. Case Rep Ophthalmol Med. 2012;2012:968180.
   PubMedGoogle Scholar
• Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120:777–787.
   PubMed Web of Science ®Google Scholar
• Letko E, Yeh S, Foster CS, et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015;122:939–948.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Quartier P, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62:1792–1802.
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Miserocchi E, Bodaghi B, et al. Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2015;42:706–711.
   PubMed Web of Science ®Google Scholar
• Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis- a case report. J Rheumatol. 2008;35:1897–1898.
   PubMed Web of Science ®Google Scholar
• Elhai M, Deslandre CJ, Kahan A, Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al. Arthritis Care Res (Hoboken). 2011;63:307–308. author reply 308.
   PubMed Web of Science ®Google Scholar
• Kenawy N, Cleary G, Mewar D, et al. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2011;249:297–300.
   PubMed Web of Science ®Google Scholar
• Marrani E, Paganelli V, De Libero C, et al. Long-term efficacy of abatacept in pediatric patients with idiopathic uveitis: a case series. Graefes Arch Clin Exp Ophthalmol. 2015;253:1813–1816.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Rituximab for ANCA-associated vasculitides. Clin Exp Rheumatol. 2014;32:S118–121.
   PubMed Web of Science ®Google Scholar
• Feurer E, Bielefeld P, Saadoun D, et al. [Biologics in uveitis]. Rev Med Interne. 2015;36:107–116.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13:246–252.
   PubMed Web of Science ®Google Scholar
• Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am J Ophthalmol. 2008;146:845–850.
   PubMed Web of Science ®Google Scholar
• Nuñez-Sotelo CM, Gutiérrez-Gonzalez LA, Rodriguez MA. Rapid, complete and sustained response to corticosteroids and pulse cyclophosphamide therapy in a patient with behçet and central nervous disease. Maedica (Buchar). 2012 Dec;7(4):348–351.
   PubMedGoogle Scholar
• Lin P, Suhler EB, Rosenbaum JT. The future of uveitis treatment. Ophthalmology. 2014;121:365–376.
   PubMed Web of Science ®Google Scholar
• Adan A, Mesquida M, Llorenç V, Biologic drugs in noninfectious uveitis: an update. Exp Rev Ophthalmol. 2013;8:501–516.
   Google Scholar
• Simonini G, Cantarini L, Bresci C, et al. Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmunity Reviews. 2010;9:647–683.
   Web of Science ®Google Scholar